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Abstract
Background: We investigated the impact of antimicrobials in cervicovaginal lavage (CVL) from HIV(+) and HIV(2) women on
target cell infection with HIV. Since female reproductive tract (FRT) secretions contain a spectrum of antimicrobials, we
hypothesized that CVL from healthy HIV(+) and (2) women inhibit HIV infection.
Methodology/Principal Findings: CVL from 32 HIV(+) healthy women with high CD4 counts and 15 healthy HIV(2) women
were collected by gently washing the cervicovaginal area with 10 ml of sterile normal saline. Following centrifugation, antiHIV activity in CVL was determined by incubating CVL with HIV prior to addition to TZM-bl cells. Antimicrobials and antigp160 HIV IgG antibodies were measured by ELISA. When CXCR4 and CCR5 tropic HIV-1 were incubated with CVL from
HIV(+) women prior to addition to TZM-bl cells, anti-HIV activity in CVL ranged from none to 100% inhibition depending on
the viral strains used. CVL from HIV(2) controls showed comparable anti-HIV activity. Analysis of CH077.c (clone of an R5tropic, mucosally-transmitted founder virus) viral inhibition by CVL was comparable to laboratory strains. Measurement of
CVL for antimicrobials HBD2, trappin-2/elafin, SLPI and MIP3a indicated that each was present in CVL from HIV(+) and
HIV(2) women. HBD2 and MIP3a correlated with anti-HIV activity as did anti-gp160 HIV IgG antibodies in CVL from HIV(+)
women.
Conclusions/Significance: These findings indicate that CVL from healthy HIV(+) and HIV(2) women contain innate and
adaptive defense mechanisms that inhibit HIV infection. Our data suggest that innate endogenous antimicrobials and HIVspecific IgG in the FRT can act in concert to contribute toward the anti-HIV activity of the CVL and may play a role in
inhibition of HIV transmission to women.
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We and others have shown that cells of the FRT produce and
secrete a spectrum of cytokines, chemokines, and antimicrobials
[5–8]. Several specifically inhibit HIV infection of target cells
[9,10]. Antimicrobials secreted by FRT cells include wellcharacterized anti-HIV molecules, alpha/beta defensins, lactoferrin, and secretory leukocyte protease inhibitor (SLPI), as well as
factors such as trappin-2/elafin and MIP3a, which have recently
been shown to have anti-HIV activity [9–13]. Some of these
factors such as human beta defensins 2 (HBD2) act directly to
inhibit virus [10], while others including SDF1a, RANTES,
MIP1a, and MIP1b bind to co-receptors to prevent viral entry

Introduction
Heterosexual transmission of HIV is the predominant driver of
the growing HIV pandemic [1,2]. Yet, while considerable
attention has been directed to developing topical exogenous
microbicides that reduce transmission of HIV-1, relatively little is
known about endogenous microbicides produced within the
female reproductive tract (FRT). That endogenous microbicides
in the female reproductive tract secretions might limit or prevent
HIV transmission is suggested by the relatively low risk of HIV
transmission per heterosexual coitus, from 1:122 to 1:1000 [3,4].
PLoS ONE | www.plosone.org
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into target cells [14]. Recent studies have linked the presence of
cationic polypeptides in CVL to anti-HSV and anti-HIV activity
[15,16]. Venkataraman et al. showed that when all cationic
polypeptides were depleted from the CVL, antimicrobial activity
was lost [16].
The isolation of HIV-1 in the FRT was first reported in 1986
[17]. Since then, numerous studies have reported the presence of
cell-free HIV-1 RNA, cell-associated HIV-1 RNA, proviral DNA,
and culturable virus from the cervix and vagina of pregnant and
non-pregnant infected women [18–20]. While it is clear that HIV1 is shed into the FRT, a detailed understanding of this
phenomenon and factors that affect the amount and infectivity
of virus in the FRT has not yet been elucidated. Reichelderfer et al.
reported that HIV-1 RNA levels in endocervical secretions were
highest in the week preceding menses [21]. Other studies have
shown no effect of the menstrual cycle on the amount or infectivity
of HIV-1 in the FRT [22]. In a recent study, the number of HIV-1
infected cells in endocervical secretions was reported to increase at
midcycle just after the periovulatory phase [23]. In other studies,
Cummins and colleagues showed that certain innate immune
factors in vaginal lavages were more closely associated with HIV-1
shedding in the genital mucosa than plasma viral load [24].
Whether virus is shed into the vagina from the upper FRT remains
to be determined. Whereas HIV-1 shedding in CVL secretions is
readily detectable, it remains unclear what percentage of the shed
virus is actually infectious [24,25].
In this study, we assessed the levels of multiple candidate
endogenous microbicides in cervicovaginal lavage (CVL) specimens from HIV(+) and HIV(2) women, and characterized
whether these microbicides correlate with protection from HIV
infection. Of the four microbicides analyzed, we found that the
levels of two endogenous microbicides, HBD2 and MIP3a
correlated with activity against HIV. Analysis of CVL for HIVspecific IgG of healthy HIV(+) women further indicated a positive
correlation with anti-HIV activity. These data indicate that CVL
from HIV(+) and HIV(2) women contain endogenously produced
antimicrobials and IgG (HIV+ samples) that correlate with
protection against HIV infection. Further, these findings suggest
that, as a consequence of antimicrobial activity in the lower FRT,
an environment exists for viral inactivation, which in part may
contribute to the low frequency of infectious virus found in FRT
secretions. The identification of endogenous microbicides that
inhibit HIV transmission should contribute both to our understanding of the pathogenesis of HIV-1, as well as facilitate the
development of novel microbicides capitalizing on existing host
immune mechanisms.

Table 1. HIV-1 Patient Demographicsa.

RACE

AGE

PVL

1*

B

33

2

B

23

3

B

4

GTVL

CD4
count

,400

,400

419

23,000

,400

459

35

3,300

,400

510

B

41

12,000

,400

517

5

B

38

20,000

9700

580

6

B

27

32,000

,400

583

7

B

39

67,000

,400

628

8

B

30

1,500

,400

637

9*

B

31

,400

,400

647

10

B

33

17,000

,400

685

11*

B

27

6,629

,400

772

12

B

24

10,000

,400

863

13

H

31

840

,400

426

14

H

27

9,300

,400

510

15

H

36

,400

,400

620

16

H

28

,400

,400

799

17

H

32

54,000

,400

813

18

H

31

,400

,400

899

19

H

27

3,600

460,000

901

20

H

16

5,200

4,700

1,517

21

W

28

3,500

,400

496

22*

W

22

2,100

,400

502

23

W

29

110,000

300,000

605

24

W

26

3,400

,400

631

25*

W

18

8,000

,400

637

26

W

32

,400

,400

651

27

W

30

,400

,400

677

28

W

22

7,600

,400

822

29*

W

29

870

38,000

872

30*

W

19

,400

,400

921

31

W

25

,400

,400

931

32

W

32

1,800

,400

1,277

a

CVL were recovered from HIV(+) women and stored in the HERS repository.
The lower level of detection of our viral load assay was 400 copies/ml. Women
self- identified by race as Black (B), Hispanic (H) or White (W). Also indicated is
the age of each individual, plasma viral RNA load (PVL), genital tract viral RNA
load (GTVL) and CD4 counts (cells/mm3).
*Denotes women with STDs; #1, 22, 25 had BV; #11 had Trichomonas; #9, 30
had BV/Trich; #29 had BV/fungus.
doi:10.1371/journal.pone.0011366.t001

Methods
HIV(+) Participants
Specimen collection and patient information were provided as a
part of an observational study on HIV shedding in women. This
study was conducted according to the principles expressed in the
Declaration of Helsinki. The study was approved by the Miriam
Hospital Institutional Review Board (Brown University, Providence, RI). All patients (HIV(+) and HIV(2)) provided written
informed consent for the collection of samples and subsequent
analysis. Thirty two HIV(+), sexually abstinent women (48 hrs
prior to sampling) between the ages of 16 and 41 years were
recruited from The Immunology Center, Miriam Hospital
(Table 1). Enrollment criteria included a normal menstrual
history, not on hormonal contraceptives, CD4 T cell counts
above 350 cells/mm3 (mean 713 (419–1517) cells/mm3), and no
exposure to antiretroviral (ARV) drugs. Participants agreed to
PLoS ONE | www.plosone.org

PATIENT
SUBJECT #

undergo colposcopic assessment, and were excluded for pregnancy, breastfeeding, menopause, or inter-menstrual bleeding in the
previous three months. Additionally, women were excluded if they
had douched, used any vaginal products, or had sexual intercourse
during the 48 hrs prior to CVL collection. CVL was collected by
gently washing the cervicovaginal area with 10 ml of sterile
normal saline (pH,7.2). Following CVL collection, samples were
centrifuged at 10,0006g for 5 min after which supernatants and
cell pellets were stored at 280uC until used. Women were tested
for lower genital tract infections including but not limited to
bacterial vaginosis (BV), Trichomonas vaginalis, Neisseria gonorrhea and
Candida albicans. Race and ethnicity were self-defined by the
2
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from individual patients were diluted 1:4 and incubated with virus
(MOI = 1) for 1hr at 37uC in a final volume of 100ml. Following
incubation, media was aspirated from TZM-bl cells and the virus
plus CVL mixture (100ml) was added to the cells along with 100ml
of TZM-bl media. Luciferase activity was measured as described
above. Controls included incubation of TZM-bl with virus alone,
CVL alone and cells in media. Uninfected cells were used to
determine background luminescence and data was expressed in
relative light units (RLU). To calculate percent inhibition, the
RLU values of ‘‘virus only’’ wells were averaged and set to 100%.
Values of CVL treated virus were calculated as a percentage of the
‘‘virus only’’ and then subtracted from 100 to calculate %
inhibition. Viability of TZM-bl cells upon treatment with CVL
was quantified using the CellTiter 96H AQueous One Solution
Cell Proliferation Assay (Promega) according to manufacturer’s
instructions. Briefly, reagent was added directly to cell cultures and
incubated for 30 min at 37uC followed by reading the plate in a
plate reader at OD 490nm.

women involved in the study. Analysis of plasma viral load (PVL)
and genital tract viral load (GTVL) RNA as well as CD4 counts,
age and race are shown in Table 1.

HIV(2) Participants
CVL from participants in this study were obtained from the
Rhode Island site (Miriam Hospital, Brown University, Providence, RI) of the HIV Epidemiology Research (HER) study.
Women ranged in age from 24 to 34 yrs. Race was self-defined by
the women involved in the study. CVL was collected by gently
washing the cervicovaginal area with 10 ml of sterile normal saline
(pH,7.2). Following CVL collection, samples were immediately
frozen at 280uC. At the time of analysis, samples were thawed to
room temperature, centrifuged at 10,0006g for 5 min after which
supernatants were assayed for anti-HIV activity. In preliminary
studies (not shown), we compared CVL that were centrifuged after
collection and prior to freezing with those that were freeze-thawed
once prior to centrifugation and found no differences in anti-HIV
inhibitory activity.

Measurement of antimicrobials in CVL
HIV Viral Stocks

CVL supernatants were stored at 280uC until assayed for SLPI,
MIP3a and trappin-2/elafin with ELISA test kits or ELISA
Duoset kit from R&D Systems (Minneapolis, MN) according to
the manufacturer’s protocol. Standards for each ELISA were resuspended in phosphate buffered saline (PBS). Samples were also
diluted in 1xPBS. Cytokines were quantified based on standard
curves obtained using an ELISA reader (Dynex, Chantilly, VA).
HBD2 was assayed with an ELISA test kit from PeproTech (Rocky
Hill NJ) according to the manufacturer’s protocol.

Laboratory-adapted viral strains HIV-1 IIIB (X4) and BaL (R5)
were obtained from Dr. P. Gupta (Univ. of Pittsburgh, PA). Virus
stocks were propagated in PHA-stimulated human PBMC and
stored frozen at 280uC. Virus stocks produced in PBMC of
molecularly cloned HIV-1 NL4.3 (X4; lab-adapted) and YU-2.c
(R5; directly cloned without culture) were used in this study. Virus
titers were determined on TZM-bl cells as described [26]. Also
used was a PBMC-derived virus stock of pCH077.c, a recently
generated Clade B infectious molecular clone ([27,28], Ochsenbauer et al., manuscript in preparation) matching the nucleotide
sequence determined to be the transmitted/founder virus
sequence of CHAVI subject 700010077.

Measurement of infectious HIV in CVL
Intrinsic anti-HIV activity in CVL was determined using TZMbl cells [26]. The TZM-bl indicator cell line is a HeLa cell
derivative that expresses high levels of CD4, CCR5 and CXCR4.
Cells contain HIV long terminal repeat (LTR)-driven b-galactosidase and firefly luciferase reporter cassettes that are activated by
HIV infection and subsequent Tat protein expression [26]. TZMbl cells were routinely subcultured every 3 to 4 days by
trypsinization and maintained in TZM-bl media consisting of
phenol red-free DMEM (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with 10% defined FBS (HyClone, Logan, UT,
USA), 2 mM L-glutamine (Invitrogen Life Technologies), and
50 mg/ml primocin (Invivogen, San Diego, CA, USA).
To measure the presence of infectious HIV-1 in CVL, TZM-bl
cells were seeded at 26104 cells per well in a 96-well microtiter plate
and allowed to adhere overnight at 37uC. Patient CVL samples
were diluted 1:4 in TZM-bl media prior to 100ml being added to
TZM-bl cells for 48h at 37uC in 5% CO2. Luciferase activity was
measured following manufacturer’s instructions. Briefly, following
aspiration of supernatants, a beta-glo luciferase substrate (Promega,
Madison, WI) solution (100ml) was added to cells. The light intensity
of each well was measured using a luminometer. Background
luminescence was determined by analyzing uninfected TZM-bl
cells. All infectivity assays were performed in quadruplicate. Media
diluted CVL had neutral pH values (pH 7.0–7.2).

Figure 1. Determination of the presence of infectious HIV-1 in
CVL from HIV(+) women. HIV(+) CVL from 32 patients were diluted 1:4
and added directly to TZM-bl cells. The assay was terminated 48h postinfection and HIV-1 infection was quantified by measuring luciferase
reporter gene activity using a luminometer and expressed as relative
light units (RLU). Each data point in graph represents one individual
patient. In the Control (media only) column, each point represents
replicate wells. When comparing Controls with the CVL samples (TZM-bl
cells incubated with CVL), 3 out of 32 showed RLU levels at least 2-fold
above background indicating that these 3 CVL contained infectious HIV-1
which trans-activated the LTR-driven reporter gene.
doi:10.1371/journal.pone.0011366.g001

Measurement of CVL anti-HIV-1 activity
TZM-bl cells were seeded at 26104 cells per well in a 96-well
microtiter plate and allowed to adhere overnight at 37uC. CVL
PLoS ONE | www.plosone.org
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The presence of anti-HIV gp160 specific IgG and IgA antibodies
used 15mOD as a cut-off for detection.

Measurement of anti-gp160HIV IgA and IgG antibody
levels in CVL
Specimens were tested by kinetic ELISA (kELISA) adapted
from an assay previously described for influenza [29]. The
kELISA measures substrate activation every 9 sec over the first
5 min of the enzymatic assay and plots the change in color per min
as mOD/min using a Thermomax microplate reader (Molecular
Devices, Sunnyvale, CA). Duplicate wells were coated with MN
strain gp160 (Protein Sciences, Meriden, CT). An uncoated well
was run with each sample to determine background, which was
subtracted from the result. A standard curve with a known positive
serum specimen was included in each assay as a measure of
sensitivity and reproducibility. Biotinylated anti-human IgG and
IgA conjugates were used with streptavidin-HRP and ABTS [29].

Measurement of HIV-1 RNA in CVL and Plasma
Nucleic acid sequence-based amplification (BioMerieux, Durham, NC) was used to measure HIV-1 RNA as previously
described [30]. All results are expressed as copies per ml with a
lower limit of detection of 2.6 log10 (400) copies/ml for both
plasma and CVL.

Statistical analysis
Data were analyzed using GraphPad Prism (La Jolla, CA) and
STATA 9 (College Station, TX). Mean and standard error were
calculated for all data sets. Comparisons of anti-HIV activity

Table 2. Anti-HIV-1 activity and levels of antimicrobials in secretions from HIV(+) patients.

Patient

X4

Number

IIIB

1

66

82

12

30

52

50344

10499

1942

108000

2

51

86

257

26

34

44635

7441

246

103000

3

30

82

53

26

21

2089

4260

21

55340

4

85

84

30

46

37

34056

7820

481

105000

5

62

70

220

34

27

42438

9746

346

83710
18040

NL4.3

% Inhibition

R5

YU2.c

BaL

(pg/ml)
CH077.c

HBD2

Elafin

MIP3a

SLPI

6

260

246

286

258

243

10

2705

4

7

90

87

1

81

55

48638

3226

669

112000

8

63

47

210

14

36

19925

2718

9

19510

9

65

68

65

60

89

52713

8316

1173

46800

10

23

10

14

220

32

36913

5664

405

76160

11

77

84

1

249

2134

60777

5503

4

14310

12

53

29

279

22

239

48809

7548

4

84320

13

11

220

245

14

26

23453

8248

19

87550

14

58

214

24

52

66

6539

1437

47

79190
32650

15

77

66

29

56

53

7453

6800

136

16

98

99

35

77

77

42876

1824

55

42400

17

19

23

219

28

57

1375

3182

113

22250

18

99

96

66

92

87

46164

32

15

35660

19

100

101

82

98

78

65573

8703

3409

107000

20

100

99

91

90

96

50670

4989

2469

100000

21

93

78

22

75

47

28611

3206

136

49780

22

79

27

66

15

41

22319

5328

62

38230

23

89

78

35

67

75

38803

7040

59

55380

24

25

219

23

0

25

10

226

36

12340

25

223

16

43

255

69

41898

6465

43

52480

26

261

29

25

265

231

26324

4316

146

121000

27

93

99

67

89

88

28985

3368

101

42770

28

95

93

67

63

50

49191

4307

40

27350

29

215

61

64

232

63

49555

3516

246

51640

30

95

100

92

86

96

15506

2

201

30330

31

38

62

49

31

72

37105

1894

12

8530

32

69

91

35

52

65

55500

4544

446

103000

MEDIAN

66

74

28

33

53

37954

4430

107

52060

INTERQUARTILE RANGE

28, 92

20, 89

26, 65

21, 71

30, 74

21122,
49000

2950,
7241

29, 376

31490,
93775

doi:10.1371/journal.pone.0011366.t002
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among median values for each viral strain examined. Overall, to
the best of our knowledge, this is the first demonstration of antiHIV activity in CVL from North American HIV(+) women who
are healthy, and not on ARV therapy.

between control and CVL groups were done using Mann-Whitney
U tests, with a P value of less than 0.05 considered to be
significant. We analyzed the correlation between CVL microbicide
levels and the percent reduction in HIV infection of TZM-bl cells
using Spearman correlation coefficients with a P value threshold
for statistical significance of 0.05. The percent reduction in HIV
infection of TZM-bl cells for each isolate was divided into
quartiles, and a score assigned to each quartile. Then, to assess the
impact of a given CVL microbicide with inhibition of target cell
infection across viral strains, we assessed the correlation of levels of
each endogenous microbicide with summed quartile scores using
Spearman correlation coefficients as above.

CVL from HIV(2) women have anti-HIV activity
To evaluate whether CVL from HIV(2) women had endogenous anti-HIV activity, samples from 15 healthy women were
obtained from the RI HER Repository. As shown in Table 3, we
found general inhibition of HIV infection of target cells. Similar to
HIV(+) women, CVL from HIV(2) women showed limited
enhancement of HIV infectivity beyond control infections (3 of 75
assays). Although 5/15 HIV(2) women had BV (# 3,4,5,10,15),

Results
Infectious HIV-1 in Cervical Vaginal Lavage (CVL)
specimens from HIV(+) women
Table 1 shows the patient profiles of HIV(+) women indicating
age, race/ethnicity, CD4 count, plasma HIV viral load (PVL)
and genital tract HIV viral load (GTVL). Owing to the
conditions under which samples were collected, CVL were not
collected according to the menstrual cycle stage. Since current
methods of measuring GTVL do not distinguish between
infectious and non-infectious HIV [24,25], we used the TZMbl assay to measure HIV infectivity of CVL specimens and
correlated these data with GTVL, and PVL in our HIV(+)
patient population. We evaluated 32 CVL from HIV infected
women for infectious virus. CVL were obtained from HIV(+)
women, who had CD4+ cell counts greater than 350 cells/mm3
and were not on anti-retroviral (ARV) therapy. Samples were
diluted 1:4 in media (final pH 7.0–7.2) and added to TZM-bl
cells to assess whether virus present in CVL was infectious. As
shown in Figure 1, CVL from 3 of 32 women contained virus
capable of infecting TZM-bl cells. On further analysis, we
observed that of the three women, 2 had bacterial vaginosis, a
known enhancement factor for HIV infection [31], and 1 had a
Trichomonas infection. We found no correlation between GTVL
(Table 1), PVL, and infectious virus in CVL. Of the 3 women
with infectious virus (# 11, 25, 29), all had MIP3a and HIV
specific IgG levels that were lower than average (Table 2).

CVL from HIV(+) women have anti-HIV activity
To determine whether CVL from HIV(+) women inhibit HIV
infection of target cells, CVL were incubated with either X4- or
R5- tropic HIV-1 at MOI = 1 for 1h at 37uC prior to the
measurement of HIV-1 infectivity via the TZM-bl assay. Among
individual subjects, we found a spectrum of anti-HIV activity
ranging from 2134% to 100% inhibition in CVL (Figure 2). In
Table 2, as has been reported by others [32–36], we found that
some CVL, rather than inhibiting HIV infection, had a
stimulatory effect on HIV infectivity without changing background
RLU values. Values reported as less than 0% in Table 2 indicate
stimulation and are included for completeness. The demonstration
of enhancement of viral infection beyond control HIV infection
was observed in 33 of 160 assays (20%). The pattern of inhibition
was not consistent across viral strains, except in Subject 6 who had
below average levels of endogenous microbicides. As seen in
Table 2, when compared to virus alone, anti-HIV activity was
measurable against both X4 and R5 viruses for the majority of
CVL tested. In particular, we found that CVL from some patients
had anti-HIV activity between 86–100% across all viruses
examined (Patients # 20 and 30). In other cases, we found that
anti-HIV activity varied with the virus tested (Patients # 7 and
21). As seen in Table 2, no significant differences were observed
PLoS ONE | www.plosone.org

Figure 2. Measurement of antiviral activity in CVL from HIV(+)
women. Thirty two HIV(+) CVL were diluted 1:4 and incubated with
HIV-1 IIIB (X4-tropic) and BaL (R5-tropic) (Panel A) or NL4.3 (X4) and
YU-2.c (R5) (Panel B) at a multiplicity of infection (MOI) of 1 for 1h at
37uC prior to infecting TZM-bl cells. Data points in each graph
represents one individual patient. Media, ‘‘Control’’, and ‘‘CVL only’’
wells (Panel A) were set up as negative controls, and replica wells of
virus (IIIB, BaL, NL4.3 and YU-2.c) were set up as positive controls.
Significant differences (p values) between the mean of the control
(virus alone) and that of the cognate virus+CVL are shown in the
Figure.
doi:10.1371/journal.pone.0011366.g002
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Table 3. Anti-HIV-1 activity and levels of antimicrobials in CVL from HIV(2) women.

Patient

%
Inhibition R5

X4

(pg/ml)

Number

IIIB

NL4.3

YU-2.c

BaL

CH077c

HBD2

Elafin

MIP3a

SLPI

1

14

79

41

29

73

67455

18792

53

75520

2

70

91

39

66

71

20308

15764

76

51880

3

47

85

85

41

82

5487

1892

39

6000

4

66

71

93

26

87

222

4606

26

58520

5

104

97

98

31

96

1780

141

118

19190

6

34

90

44

42

78

3306

6459

124

75810

7

92

94

89

59

96

22288

2327

97

67570

8

69

85

59

22

75

906

2238

448

112000

9

46

10

66

21

50

19599

14456

90

48170

10

84

93

70

27

75

1067

3849

155

91070

11

75

77

69

18

79

4

5952

721

45080

12

101

103

105

98

74

115

214

4344

93330

13

61

92

3

59

69

27028

12821

29

51720

14

5

12

40

227

77

45

6412

71

39960

15

61

71

24

15

64

2394

8647

239

73560

MEDIAN

66

85

66

29

75

2394

5952

97

58520

INTERQUARTILE RANGE

46, 84

71, 93

40, 89

15, 59

71, 82

222, 20308

2238, 12821

53, 239

45080, 75810

doi:10.1371/journal.pone.0011366.t003

we found no correlations of these samples with anti-HIV activity.
As seen in Figures 3A and B, we found that some CVL had potent
anti-HIV activity while others had little to no activity. As with
HIV(+) healthy women, there was a wide diversity of CVL
inhibition with individual viruses.

4 known anti-HIV molecules measured in individual CVL
samples. Analysis of CVL from HIV(+) and (2) women for
SLPI, trappin-2/elafin, MIP3a, and HBD2 indicated that each
of these antivirals are present in CVL irrespective of HIV
status. Recognizing that CVL specimens from HIV(+) and (2)
women were obtained at different times and from different
repositories with slightly different protocols, it was surprising to
observe that concentrations of MIP3a and SLPI were virtually
identical (Tables 2 and 3). Moreover, the concentrations of
SLPI in CVL in our studies were comparable to that reported
previously by others [15]. Unexpectedly, we found that HBD2
levels were approximately 3-fold greater in HIV(+) women than
that seen in HIV(2) women. In contrast, HIV(2) women had
significantly (p,0.05) higher values of trappin-2/elafin than
HIV(+) women. These data suggest that HIV infection alters
the distribution of some endogenous microbicides in FRT
secretions.

Antiviral activity in CVL from HIV(+) and HIV(2) women
against an infectious molecularly cloned, transmitted/
founder virus
Recent studies focusing on initial HIV transmission have
identified the genetic sequences of transmitted/founder HIV-1
viruses responsible for the establishment of initial infection [27].
We evaluated the impact of CVL from HIV(+) and HIV(2)
women on infectivity of an infectious molecular clone containing
the complete nucleotide sequences of transmitted/founder virus,
CH077.c (Ochsenbauer et al. in preparation). As shown in
Figures 4A and 4B, when anti-HIV activity was evaluated between
different viruses, we found that transmitted/founder virus
(CH077.c) was inhibited by CVL from both healthy HIV(+) and
HIV(2) women as were laboratory-adapted viruses (IIIB, NL4.3,
BaL, and YU-2.c) shown in Tables 2 and 3. These findings suggest
that the CH077.c transmitted/founder virus is as susceptible to
inhibition by FRT endogenous microbicides as the other strains
tested.

Anti-gp160HIV IgA and IgG antibodies in CVL from HIV(+)
women
To determine whether the CVL of HIV(+) women had
antibodies against HIV, we assessed CVL samples for the presence
of anti-HIV gp160 specific IgG and IgA antibodies using 15 mOD
as a cut-off for detection [29]. As seen in Table 4, we found that 30
out of 32 CVL from HIV(+) women had anti-gp160HIV IgG
antibodies, while none were positive for anti-HIV IgA antibodies
(data not shown). Neither anti-HIV gp160 IgG nor IgA antibodies
were detected in CVL from HIV(2) women (Table 4).

CVL from HIV(+) and (2) women contain a spectrum of
antimicrobials
To define the mechanism(s) through which CVL from
HIV(+) and (2) women protect target cells from HIV infection,
we analyzed CVL specimens for key endogenous microbicide
candidates which we and others have shown in cell culture to
have antiviral activity [9–12]. Tables 2 and 3 contain a detailed
breakdown of anti-HIV activity as well as the concentrations of
PLoS ONE | www.plosone.org

Anti-HIV activity correlates with specific antimicrobials
and anti-HIV IgG in CVL from HIV(+) women.
Table 5 summarizes the correlation by Spearman analysis
between % inhibition of HIV infection of target cells by each
6
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Figure 3. Analysis of antiviral activity in CVL from HIV(2)
women. Fifteen HIV(2) CVL were diluted 1:4 and incubated with HIV-1
IIIB (X4-tropic) and BaL (R5-tropic) (Panel A) or NL4.3 (X4) and YU-2.c
(R5) (Panel B) at MOI 1 for 1h at 37uC prior to infecting TZM-bl cells.
Media only ‘‘Control’’ and virus only (IIIB, BaL, NL4.3 and YU-2.c) wells
were set up as positive controls. Each data point in graph represents
one individual patient. Data points in each graph represents one
individual patient. Significant differences between control (virus alone)
and virus+CVL are indicated in Figure.
doi:10.1371/journal.pone.0011366.g003

Figure 4. Analysis of CH077.c (R5; transmitted/founder Virus)
activity in CVL from HIV(+) and HIV(2) women. Thirty two HIV(+)
CVL and 15 HIV(2) CVL were diluted 1:4 and incubated with the R5
transmitted/founder HIV-1 virus CH077.c at MOI 1 for 1h at 37uC prior to
infecting TZM-bl cells. Control wells incubated with CVL alone were set
up as negative controls and CH077.c wells were set up as positive
controls. Each data point in Figure 4A represents one of 32 individual
patients. In Figure 4B each data point represents one of 15 individuals.
Significant differences between control (CH077.c) and CH077.c + CVL
are indicated in Figure.
doi:10.1371/journal.pone.0011366.g004

strain of HIV with concentrations of the four antimicrobials
(HBD2, trappin-2/elafin, MIP3a, SLPI) and anti-HIV gp160 IgG.
Of the 4 antimicrobials tested, we found positive correlations
between the levels of HBD2 and MIP3a as well as anti-HIV IgG
with inhibition of some HIV strains. In particular, MIP3a
correlated with anti-HIV activity against all 3 of the R5 viruses
but neither of the X4 viruses. In contrast, we found no correlation
of anti-HIV activity with SLPI and trappin-2/elafin. Similarly,
when we analyzed HBD2, MIP3a trappin-2/elafin, and SLPI vs
anti-HIV activity in CVL from HIV(2) women, we found no
evidence of a positive correlation (data not shown).
To further assess the overall contribution of each antimicrobial
and anti-HIV IgG for protection against multiple HIV viral
strains, the percent reduction in HIV infection of TZM-bl cells for
each isolate was divided into quartiles, and a score assigned to
each quartile. Then we assessed the correlation of levels of each
antimicrobial or anti-HIV IgG with the summed quartile scores
using Spearman correlation coefficients as above. As seen in
Table 5 (right column), we found significant correlations, identical
to that seen above with Spearman analysis, between the levels of
HBD2, MIP3a and anti-HIV IgG with the summed percent
PLoS ONE | www.plosone.org

reduction in HIV infection. These data are further supportive
evidence of the importance of HBD2, MIP3a and anti-HIV IgG
in protecting the FRT from multiple strains of HIV.

Discussion
The present study evaluated the presence of anti-HIV activity in
CVL from HIV(+) healthy and HIV(2) women. When analyzed
by ELISA, CVL from HIV(+) and HIV(2) women were found to
contain a spectrum of endogenous microbicides with activity
against both X4- and R5-tropic HIV.
When CXCR4 and CCR5 tropic HIV-1 were incubated with
CVL from HIV(+) women prior to addition to TZM-bl cells, anti7
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activity [13,14,37–39]. Unexpectedly, in the present study, we
found that anti-HIV-1 activity in CVL from HIV(+) women
correlated with CVL levels of MIP3a and HBD2 but not with
SLPI or trappin-2/elafin. Interestingly, MIP3a concentrations in
HIV(+) CVL positively correlated with anti-HIV activity against
all 3 R5 HIV strains, including the transmitted/founder virus
CH077.c. In addition, anti-HIV activity in CVL from HIV(+)
women correlated significantly with anti-gp160HIV IgG antibodies. This is the first study to correlate anti-HIV activity of healthy
HIV(+) CVL from North American women with the levels of antiHIV antibodies. While we have not established that these
antibodies possess neutralizing ability, these data clearly suggest
a role for antibodies in the immune defense against HIV
transmission. Taken together, these findings indicate that CVL
from HIV(+) and (2) women contain endogenously produced
antimicrobials that inhibit HIV infection, and in doing so may
limit both acquisition and transmission of infection.
An unexpected finding was that approximately 3/32 samples
from HIV(+) CVL examined contained virus capable of infection,
and that infectious virus was independent of plasma and genital
tract viral load. While very few studies have measured infectious
virus in CVL, others have reported similar low numbers of women
with CVL infectious virus [24]. In our study, the 3 women with
infectious virus had MIP3a and HIV-specific IgG levels that were
lower than average (Table 2 and Table 4). This finding suggests
that endogenous antimicrobials such as MIP3a and HIV-specific
IgG antibodies are too low to inactivate virus. These findings are
of particular importance because they suggest that local protection
in CVL may inactivate infectious virus to limit sexual transmission.
Others have demonstrated that low vaginal pH can inactivate
HIV [40]. That this is unlikely is suggested from studies in which
vaginal pH was measured both prior to and immediately following
ejaculation. In all cases, vaginal pH was neutralized from 5.6 to
7.2 within 6 seconds [41,42]. These findings suggest that
antivirals, such as MIP3a measured in the present study along
with other endogenous microbicides, are responsible for viral
inactivation. Further studies are essential to identify the molecules
involved in limiting the presence of infectious virus in genital tract
secretions.
It is well established that during sexual transmission, R5 strains
of HIV are selectively transmitted over X4 strains, although the
mechanisms for this are poorly understood [43–45]. An unexpected finding in the present study was the variation in antiviral
activity in CVL specimens between individuals and against
different viruses. This range of inhibition existed between viruses
of the same tropism (X4: IIIB and NL4.3; R5: BaL, YU-2.c and
CH077.c) and was independent of subject demographic characteristics. One explanation is that variations in viral envelopes
might lead to differences in sensitivity to antivirals in CVL. For
example, SLPI and defensins have been shown to inhibit HIV
infection based on tropism [46,47]. Alternatively, since CVL
contain a spectrum of antimicrobials that vary with stage of the
menstrual cycle [15], it is likely that variations in both the quality
and quantity of antimicrobials between individuals contribute to
the diversity of antiviral activity seen in this study. The observation
that MIP3a, which we have shown to inhibit HIV infection [13],
correlated positively with anti-HIV activity against the R5, but not
the X4, HIV strains suggests a unique protective role for this
antimicrobial against HIV-1 infection. Whether viral differences,
cycle stage or heterogeneity of antimicrobials in CVL samples are
responsible remains to be determined.
Anti-HIV activity of CVL from HIV(2) women did not
correlate with the levels of any of the measured microbicides (data
not shown). One explanation for this finding is that the number of

Table 4. HIV GP160-specific IgG in CVL from HIV(+) and
HIV(2) women.

Patient #

32 HIV+
Patient ID

IgG

15 HIVPatient ID

IgG

1

B071c

583

40048

1.7

2

B083c

907

400993

1.7

3

B037c

148

400415

1.7

4

B057c

645

402382

1.5

5

B060a

.1000

402757

1.2

6

B059c

13

401687

1.8

7

B013c

.1000

400868

1.4

8

B006c

37

401927

1.2

9

B078c

1106

400937

0.7

10

B062a

745

401541

1

11

B011a

272

401701

1.5

12

B027c

1190

400802

12.6

13

B074c

29

400824

2.2

14

B061c

43

402428

1.6

15

B079c

529

400982

0.4

16

B015a

562

17

B086d/a

107

18

B073b

532

19

B068c

.1000

20

B018c

.1000

21

B012c/a

233

22

B067c

26

23

B077d/a

95

24

B051d/c

2.7

25

B085c/a

25

26

B017c

54

27

B029c

914

28

B048c

134

29

B049c

128

30

B047c

534

31

B058c/a

64

32

B075c

501

The results are in milliOD per minute but correspond directly to the amount of
binding antibody. 15 is the usual cut-off by this criteria, only two HIV infected
person lacked antibody. No antibodies were detected in HIV(2) CVL.
doi:10.1371/journal.pone.0011366.t004

HIV activity in CVL ranged from none to 100% inhibition with
some showing enhancement, depending on the viral strains used.
CVL from HIV(2) controls showed comparable anti-HIV activity.
Importantly, CVL from HIV(+) and HIV(2) women demonstrated potent antiviral activity against a molecular clone of a
transmitted/founder virus, CH077.c, that was comparable to
laboratory strains. Measurement of CVL for antimicrobials
demonstrated that HBD2 and MIP3a correlated with anti-HIV
activity as did anti-gp160 HIV IgG antibodies in CVL from
HIV(+) women.
The present studies demonstrate that CVL from HIV(+) and
HIV(2) women contain at least four microbicides with known
anti-HIV activity. We and others have examined SLPI, trappin-2/
elafin, MIP3a, and HBD2 and found that each has anti-HIV
PLoS ONE | www.plosone.org
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Tables 5. Correlation of levels of antimicrobials and anti-HIV IgG in CVL with anti-HIV activity against 5 different viruses.

% Reduction in Target Cell Infection with Indicated Strain
IIIB (X4)

NL4.3 (X4)

BaL (R5)

YU-2.c (R5)

CH077.c (R5)

Percent reduction against all
viruses, summed quartiles

Spearman’s r

0.391

0.28

0.53

0.288

0.283

0.395

P value

0.027

0.121

0.002

0.109

0.116

0.025

HIV+ (N = 32)
HBD2

Elafin
Spearman’s r

20.053

20.178

20.009

20.095

20.198

20.091

P value

0.772

0.331

0.961

0.605

0.277

0.619

MIP3a
Spearman’s r

0.278

0.271

0.425

0.382

0.4

0.397

P value

0.124

0.134

0.015

0.031

0.023

0.025

SLPI
Spearman’s r

0.033

20.053

0.184

0.136

20.017

0.079

P value

0.859

0.775

0.315

0.46

0.925

0.668

Anti-HIV IgG
Spearman’s r

0.484

0.117

0.595

0.517

0.283

0.502

P value

0.005

0.526

0.001

0.002

0.117

0.003

doi:10.1371/journal.pone.0011366.t005

HIV(2) CVL samples analyzed in this study [15] was too low. An
alternative explanation is that the anti-HIV activity of CVL stems
from a combination of multiple endogenous microbicides and that
the assessment of no single factor adequately captures the sum
total anti-HIV activity of any one woman’s CVL microbicides
[15,16,48]. For example, others have shown that CVL contain the
cathelicidin peptide LL37, calprotectin, alpha defensins and
lactoferrin, each of which has limited innate antimicrobial activity
but can act in synergy to inhibit HIV [9,49]. What appears not to
be involved is pH. Although low pH can selectively destabilize the
viral envelope leading to altered viral infectivity [24], all samples
tested in this study were diluted in buffered media and found to be
pH neutral (pH 7–7.2) prior to assay for anti-HIV activity.
Our studies demonstrate that CVL from a subset of women
enhanced HIV infection of target cells. This suggests that CVL
from HIV(+) women may contain factors that enhance HIV
infection. Such molecules include proinflammatory cytokines such
as IL-6, IL-8, TNFa, and IL-1â. These are often present in the
CVL in association with pre-existing infections with STI such as
bacterial vaginosis (BV), HSV-2, Trichomonas vaginalis, Neisseria
gonorrhea, and Candida albicans [50–52]. In fact, BV infection has
been frequently found to be a major correlate for enhanced HIV
replication in the FRT presumably through the enhanced
production of proinflammatory cytokines. Several of these factors
can directly enhance HIV replication by stimulating the HIV LTR
[32–34,52,53]. Another molecule found in serum and mucosal
secretions and associated with enhanced HIV replication is
myeloid related proteins MRP 8/14 [35]. Another protein, a
scavenger receptor gp340, has been shown to be expressed by
cervical and vaginal epithelium and promote trans-infection of
HIV even when the epithelium remains intact [36,54].
Some recent studies have demonstrated that the mere presence
of anti-HIV molecules in the genital tract does not necessarily
correlate with HIV neutralization activity in vivo [55,56]. This is
because some of these anti-HIV molecules such as RANTES,
LL37 and MIP3a have potent chemotactic activity and can attract
target cells to the site of infection thereby causing an enhancement
PLoS ONE | www.plosone.org

effect. Another factor that might explain the variability in HIV
neutralization ability of CVL is the amount of bioactive anti-HIV
molecules present at a given time. Bioactivity is often determined
by the presence of multiple families of proteases in the genital tract
that are responsible for specific activation and deactivation of
immune factors. The Cathepsin family of proteases regulates the
family of matrix metalloproteases, which are themselves responsible for activating/deactivating innate immune factors including
the anti-HIV molecules SDF-1 and HNP1 [57–60]. Cathepsins
are also responsible for directly regulating anti-HIV innate factors
[61–63]. For example, Cathepsin D, a cysteine protease present in
vaginal secretions [49] has been shown to enhance HIV
replication [64,65]. Although the mechanisms are unclear, it is
known that Cathepsin D inhibits MIP3a [61], a known anti-HIV
factor in CVL [13]. Kallikreins (KLK) are another family of serine
proteases present in the genital mucosa that can activate/
deactivate multiple immune factors in the FRT [66] including
LL37, a potent anti-HIV molecule [67,68]. Finally, CD26/
dipeptidyl peptidase IV (DPIV) is a serine protease responsible for
the cleavage and inactivation of chemokines such as RANTES and
SDF-1, which are involved in blocking HIV entry [69,70]. A
further level of complexity arises in that, beyond their ability to
activate and inactivate FRT antimicrobials, these protease families
are regulated throughout the menstrual cycle by protease
inhibitors present in the genital secretions. Several protease
inhibitors such as SLPI and trappin-2/elafin are also known
anti-HIV molecules [12,37,71].
We examined the role of specific endogenous microbicides in the
reduction of HIV infection of target cells by CVL from HIV(+) and
HIV(2) women, finding that the levels of HBD2 and MIP3a
correlated significantly with inhibition of infection. HBD2 is
reported to inhibit infection through direct interaction with the
virus, as well as decreasing expression of CXCR4, the co-receptor
for X4 HIV-1 viruses (but not CCR5) in peripheral blood
mononuclear cells and T lymphocytic cells as shown by confocal
microscopy and flow cytometry [46]. Sun et. al. did not find a
decrease in co-receptor expression with HBD2 treatment, and
9
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suggest an effect on the intracellular environment that inhibits HIV
[72]. We found that HBD2 and SLPI are present in CVL at
concentrations comparable to previous reports [15,73,74]. Notably,
CVL from HIV(+) women had significantly higher HBD2 than
HIV(2) women, suggesting that HIV infection upregulates the
production of this potentially protective endogenous microbicide.
One explanation for the variability seen in anti-HIV activity
(innate and specific IgG antibodies) in the present study is that it
was not possible to collect CVL from HIV(2) and HIV(+) women
according to stage of the menstrual cycle. As discussed elsewhere
[48], innate and adaptive immunity throughout the female
reproductive tract are under hormonal control. For example, we
found that midcycle suppression of the humoral immunity by
estradiol, which confirms the findings of other laboratories [75,76],
extends to endogenous antimicrobials in CVL [15]. Analysis of the
concentrations of cytokines, chemokines and antimicrobials in
CVL indicated that SLPI, HBD2, HNP1-3 and lactoferrin
dropped significantly at midcycle (day 13) and remained depressed
for 7–10 days prior to returning to proliferative phase levels just
prior to menstruation. Therefore, owing to hormonal changes
during the menstrual cycle, antimicrobials and antibodies may not
be present at concentrations sufficient to exert anti-HIV effects.
Thus, without compensating mechanisms, innate immune protection is suppressed transiently at midcycle to optimize the chances
for successful fertilization, implantation and pregnancy. What is
likely is that antiviral activity in CVL is the net and possibly
synergistic result of 12–20 antimicrobials present at varying
concentrations over the course of the menstrual cycle. Studies to
assess the spectrum of antimicrobials in CVL and the ways in
which each is altered during the menstrual cycle are essential for a
complete understanding of the role of the innate immune system in
protection and control of sexual transmission of HIV.
Other studies have demonstrated the presence of anti-HIV
antibodies in CVL from HIV(+) women [1,77–79], but to the best
of our knowledge, ours is the first to correlate the levels of these
antibodies with anti-HIV activity in CVL from healthy North
American HIV(+) women not on any ARVs. These results should
prompt an assessment of whether these antibodies exhibit
neutralizing activity against HIV, or if the correlation with
protection of target cells arises from other mechanisms. Binding
but non-neutralizing IgG in the CVL of HIV(+) women has been

shown to be protective by lowering viral loads and presenting
better clinical outcomes [80]. Such antibodies are believed to
protect by inducing ADCC (antibody dependent cellular cytotoxicity) and ADCVI (Antibody dependent cell mediated viral
inhibition) [81]. In fact, the recent vaccine trial in Thailand shows
preliminary data indicative of protective effects from binding but
non-neutralizing antibodies [82]. We also found, similar to other
studies [78,79,83], that CVL from HIV(+) women lacked antiHIV specific IgA antibodies, suggesting that IgA in the FRT might
not play a substantive role in protection from HIV transmission.
In summary, this study demonstrates that CVL from healthy
HIV(+) and HIV(2) women have intrinsic anti-HIV activity and
that this activity is most likely mediated through a spectrum of
endogenously produced antimicrobials which are capable of
inhibiting X4 and R5 viruses. Whereas a spectrum of factors
capable of mediating antimicrobial protection are present in CVL,
the levels of HBD2, MIP3a and HIV specific IgG antibodies
correlated with protection of target cells from infection with HIV.
These findings highlight the need for additional studies to more
fully understand the influences of the innate immune system and
its regulation by sex hormones during the menstrual cycle,
pregnancy and following menopause in immune protection
throughout the reproductive tract. Moreover, it suggests that a
clear understanding of innate protection in the female reproductive tract may lead to new candidate microbicides and approaches
for microbicide-mediated immune protection.
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